Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:15:33.972Z.
Consensus retrieved: 2026-10-06T08:31:14.256Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:15:33.972Z.
Quote observation: 2026-10-06T14:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f641a2bf51a69a6e8cdb13afe7e76557325a462d28890c99da58f5868e3b8e6
Forward PE Ratio (N/A) = Dated Quote Price ($31.07) / Consensus Forward EPS ($-5.68)
FORWARD PE RATIO
N/A
Agios Pharmaceuticals, Inc.
Market Cap
$1.86B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.86B | N/A |
| Absci Corporation (ABSI)vs › | $1.84B | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 26.47 |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.83B | 27.83 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.35 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.94B | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.75B | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | N/A |
| Immunome, Inc. (IMNM)vs › | $1.98B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 5.66 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $31.07, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.68 | $-6.76 – $-5.08 | 8 | n/m |
| 2027-12-31 | $-3.70 | $-5.44 – $-2.33 | 9 | n/m |
| 2028-12-31 | $-1.72 | $-3.53 – $0.49 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
